36.22 USD
-0.19 (-0.52%)
36.22 USD
0 (0%)
Overall HRMY gets a fundamental rating of 8 out of 10. We evaluated HRMY against 190 industry peers in the Pharmaceuticals industry. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. These ratings would make HRMY suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
- HRMY had positive earnings in the past year.
- HRMY had a positive operating cash flow in the past year.
- Of the past 5 years HRMY 4 years were profitable.
- HRMY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- HRMY has a Return On Assets of 15.37%. This is amongst the best in the industry. HRMY outperforms 95.26% of its industry peers.
- HRMY has a Return On Equity of 22.23%. This is amongst the best in the industry. HRMY outperforms 92.63% of its industry peers.
- HRMY's Return On Invested Capital of 17.20% is amongst the best of the industry. HRMY outperforms 94.74% of its industry peers.
- HRMY had an Average Return On Invested Capital over the past 3 years of 18.27%. This is significantly above the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
- HRMY has a better Profit Margin (22.48%) than 91.58% of its industry peers.
- HRMY's Profit Margin has improved in the last couple of years.
- HRMY has a Operating Margin of 27.32%. This is amongst the best in the industry. HRMY outperforms 93.16% of its industry peers.
- HRMY's Operating Margin has declined in the last couple of years.
- HRMY has a Gross Margin of 77.70%. This is amongst the best in the industry. HRMY outperforms 83.16% of its industry peers.
- HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HRMY is creating value.
- HRMY has more shares outstanding than it did 1 year ago.
- HRMY has less shares outstanding than it did 5 years ago.
- HRMY has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.44 indicates that HRMY is not in any danger for bankruptcy at the moment.
- With a decent Altman-Z score value of 5.44, HRMY is doing good in the industry, outperforming 74.74% of the companies in the same industry.
- HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
- HRMY has a better Debt to FCF ratio (0.57) than 96.84% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that HRMY is not too dependend on debt financing.
- The Debt to Equity ratio of HRMY (0.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.44 |
ROIC/WACC1.8
WACC9.55%
2.3 Liquidity
- A Current Ratio of 3.75 indicates that HRMY has no problem at all paying its short term obligations.
- The Current ratio of HRMY (3.75) is comparable to the rest of the industry.
- HRMY has a Quick Ratio of 3.72. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
- HRMY's Quick ratio of 3.72 is in line compared to the rest of the industry. HRMY outperforms 58.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
- HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.71%, which is quite impressive.
- The Earnings Per Share has been growing by 44.61% on average over the past years. This is a very strong growth
- HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.13%.
- HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
- The Earnings Per Share is expected to grow by 35.10% on average over the next years. This is a very strong growth
- HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.79% yearly.
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.79%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- HRMY is valuated reasonably with a Price/Earnings ratio of 11.39.
- Based on the Price/Earnings ratio, HRMY is valued cheaper than 89.47% of the companies in the same industry.
- HRMY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.47.
- With a Price/Forward Earnings ratio of 8.57, the valuation of HRMY can be described as very reasonable.
- HRMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 90.53% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of HRMY to the average of the S&P500 Index (24.26), we can say HRMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.39 | ||
| Fwd PE | 8.57 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 94.74% of the companies listed in the same industry.
- 96.32% of the companies in the same industry are more expensive than HRMY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.03 | ||
| EV/EBITDA | 6.28 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of HRMY may justify a higher PE ratio.
- HRMY's earnings are expected to grow with 25.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25%
5. Dividend
5.1 Amount
- HRMY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
36.22
-0.19 (-0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners85.16%
Inst Owner Change2.11%
Ins Owners1.63%
Ins Owner Change-61.8%
Market Cap2.09B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target47.11 (30.07%)
Short Float %8.89%
Short Ratio5.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)0%
PT rev (3m)3.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.87%
EPS NY rev (1m)0%
EPS NY rev (3m)2.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.39 | ||
| Fwd PE | 8.57 | ||
| P/S | 2.53 | ||
| P/FCF | 7.03 | ||
| P/OCF | 7.01 | ||
| P/B | 2.5 | ||
| P/tB | 2.82 | ||
| EV/EBITDA | 6.28 |
EPS(TTM)3.18
EY8.78%
EPS(NY)4.23
Fwd EY11.67%
FCF(TTM)5.15
FCFY14.23%
OCF(TTM)5.17
OCFY14.27%
SpS14.34
BVpS14.5
TBVpS12.84
PEG (NY)0.38
PEG (5Y)N/A
Graham Number32.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.44 |
F-Score6
WACC9.55%
ROIC/WACC1.8
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.79%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year37.1%
EBIT Next 3Y27.64%
EBIT Next 5Y23.54%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What are the PE and PB ratios of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 11.39 and the Price/Book (PB) ratio is 2.5.
What is the earnings growth outlook for HARMONY BIOSCIENCES HOLDINGS?
The Earnings per Share (EPS) of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 29.83% in the next year.